Reading the tape
NASDAQ: SRZN
Surrozen, Inc.
Healthcare · Biotechnology
Market Cap
$240.44M
52w High
$35.00
52w Low
$5.90
P/E
-0.99
Volume
49.83K
Outstanding Shares
7.48M
Price vs Fundamentals
Why The Stock Is Moving
Momentum disconnected from fundamentalsModerate confidence
Note: The most recent financial data is over 3 months old. Metrics shown may not reflect the latest reporting period.
1Y Price: 216.32%Revenue (TTM): -67.37%FCF (TTM): -72.04%P/S: 100th pct
What changed
The stock rose 216.32% over the last year. Revenue declined 67.37% over the trailing twelve months. Operating margin moved from -239.69% to -1,210.58%. Free cash flow declined 72.04% over the trailing twelve months.
What the market seems to be pricing
The stock is rising despite deteriorating fundamentals and now sits at the 100th percentile of its historical P/S range. This is a momentum-driven move — the market may be front-running a recovery that has not yet appeared in reported numbers.
What would invalidate this read
Operating margin (currently -1,210.58%) would need to stabilize or improve to justify the move. Revenue is declining 67.37% — a trend reversal in the next report would be the key signal to watch. This read is wrong if the next period shows operating metrics turning the corner. At that point the price would be anticipating real improvement rather than running ahead of it.
Company profile
Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair and regeneration.
CEOCraig C. Parker
SectorHealthcare
IndustryBiotechnology
Employees40
IPO dateJan 11, 2021
Valuation
Forward P/E—
EV/EBITDA-2.08
Enterprise value$86.4M
Stock splits
Dec 14, 2023↓ Reverse
Every 15 shares became 1
Profitability & growth
Revenue growth-19.39%
Gross margin98.71%▼15.44%vs FY2024
Operating margin-1,210.58%▼405.06%vs FY2024
ROE128.9%▼56.64%vs FY2024
Analyst consensus
RatingBuy
Target price$40.00▲24.40%
4
Buy
0
Hold
2
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
May 8, 2026
Q2 FY26 · EPS est -$1.09 · Revenue est $4M
View